Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.

Spellberg B, Nielsen TB, Gilbert DN, Shorr AF, Brass EP.

Ann Intern Med. 2019 Oct 8. doi: 10.7326/M19-1893. [Epub ahead of print] No abstract available.

PMID:
31590184
2.

Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

Nielsen TB, Brass EP, Gilbert DN, Bartlett JG, Spellberg B.

N Engl J Med. 2019 Aug 8;381(6):503-505. doi: 10.1056/NEJMp1905589. Epub 2019 Jun 19. No abstract available.

3.

The Effectiveness of Nonprescription Drug Labels in the United States: Insights from Recent Research and Opportunities for the Future.

Catlin JR, Brass EP.

Pharmacy (Basel). 2018 Oct 26;6(4). pii: E119. doi: 10.3390/pharmacy6040119. Review.

4.

Poison center exposures due to therapeutic misuse of nonprescription acetaminophen-containing combination products in the United States 2007-2016.

Brass EP, Burnham RI, Reynolds KM.

Clin Toxicol (Phila). 2019 May;57(5):350-355. doi: 10.1080/15563650.2018.1517879. Epub 2018 Oct 11.

PMID:
30306812
5.

Frequency of Poison Center Exposures for Pediatric Accidental Unsupervised Ingestions of Acetaminophen after the Introduction of Flow Restrictors.

Brass EP, Reynolds KM, Burnham RI, Green JL.

J Pediatr. 2018 Jul;198:254-259.e1. doi: 10.1016/j.jpeds.2018.02.033. Epub 2018 Apr 2.

6.

Response by Brass and Hiatt to Letter Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease".

Brass EP, Hiatt WR.

Circulation. 2018 Mar 20;137(12):1304. doi: 10.1161/CIRCULATIONAHA.117.032707. No abstract available.

PMID:
29555719
7.

Medication Errors With Pediatric Liquid Acetaminophen After Standardization of Concentration and Packaging Improvements.

Brass EP, Reynolds KM, Burnham RI, Green JL.

Acad Pediatr. 2018 Jul;18(5):563-568. doi: 10.1016/j.acap.2018.03.001. Epub 2018 Mar 6.

8.

Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease.

Brass EP, Hiatt WR.

Circulation. 2017 Aug 29;136(9):785-786. doi: 10.1161/CIRCULATIONAHA.117.028888. No abstract available.

PMID:
28847795
9.

Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good.

Spellberg B, Marr KA, Brass EP.

Clin Pharmacol Ther. 2016 Dec;100(6):597-599. doi: 10.1002/cpt.510. Epub 2016 Oct 14.

10.

Time Trends in Physician Visits for Gastroesophageal Reflux Disease Before and After the Rx-to-OTC Switch of Proton Pump Inhibitors.

Chang DW, Grotts J, Tseng CH, Brass EP.

J Clin Pharmacol. 2017 Apr;57(4):452-458. doi: 10.1002/jcph.825. Epub 2016 Oct 6. No abstract available.

PMID:
27599455
11.

Noninferiority Doesn't Mean Not Inferior.

Spellberg B, Brass EP.

Clin Infect Dis. 2016 Feb 15;62(4):525-6. doi: 10.1093/cid/civ895. Epub 2015 Oct 20. No abstract available.

PMID:
26486703
12.

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.

Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S.

Clin Pharmacol Ther. 2015 Nov;98(5):522-33. doi: 10.1002/cpt.203. Epub 2015 Sep 11. Review.

13.

Mitochondria as targets of drug toxicity: Lessons from the R118 phase I experience.

Brass EP, Hoppel CL.

Clin Pharmacol Ther. 2015 Nov;98(5):464-6. doi: 10.1002/cpt.160. Epub 2015 Jul 28.

PMID:
26059062
14.

Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease.

Hiatt WR, Armstrong EJ, Larson CJ, Brass EP.

Circ Res. 2015 Apr 24;116(9):1527-39. doi: 10.1161/CIRCRESAHA.116.303566. Review.

PMID:
25908726
15.

Response to McDermott.

Hiatt WR, Rogers K, Brass EP.

Circulation. 2014 Jul 1;130(1):68. No abstract available.

PMID:
25110791
16.

The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease.

Hiatt WR, Rogers RK, Brass EP.

Circulation. 2014 Jul 1;130(1):69-78. doi: 10.1161/CIRCULATIONAHA.113.007003. Review. No abstract available.

PMID:
24982118
17.

Patient and hospital-level characteristics associated with the use of do-not-resuscitate orders in patients hospitalized for sepsis.

Chang DW, Brass EP.

J Gen Intern Med. 2014 Sep;29(9):1256-62. doi: 10.1007/s11606-014-2906-x. Epub 2014 Jun 14.

18.

The Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes.

Brass EP.

Diabetes Spectr. 2014 May;27(2):75-7. doi: 10.2337/diaspect.27.2.75. No abstract available.

19.

Resident's morning report: an opportunity to reinforce principles of biomedical science in a clinical context.

Brass EP.

Biochem Mol Biol Educ. 2013 Sep-Oct;41(5):315-8. doi: 10.1002/bmb.20714. Epub 2013 Sep 10.

20.

Cardiovascular risks with azithromycin.

Brass EP.

N Engl J Med. 2013 Aug 8;369(6):580. doi: 10.1056/NEJMc1306999. No abstract available.

PMID:
23924018
21.

Intermittent claudication: new targets for drug development.

Brass EP.

Drugs. 2013 Jul;73(10):999-1014. doi: 10.1007/s40265-013-0078-3. Review.

PMID:
23775528
22.
23.

Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease.

Brass EP, Cooper LT, Hanson P, Hiatt WR.

J Vasc Surg. 2013 Aug;58(2):396-403. doi: 10.1016/j.jvs.2012.12.077. Epub 2013 May 16.

24.

From bad behaviour to bad biology: pitfalls and promises in the management of resistant hypertension.

Feldman RD, Brass EP.

Can J Cardiol. 2013 May;29(5):549-56. doi: 10.1016/j.cjca.2013.02.009. Review.

PMID:
23618504
25.

A decision-analysis tool for benefit-risk assessment of nonprescription drugs.

Brass EP, Lofstedt R, Renn O.

J Clin Pharmacol. 2013 May;53(5):475-82. doi: 10.1002/jcph.22. Epub 2013 Feb 4. Review.

PMID:
23381796
26.

A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication.

Brass EP, Koster D, Hiatt WR, Amato A.

Vasc Med. 2013 Feb;18(1):3-12. doi: 10.1177/1358863X12467491. Epub 2013 Jan 15. Review.

PMID:
23321261
27.

Risk factors for mortality in patients with mucormycosis.

Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, Ibrahim AS, Brass EP.

Med Mycol. 2012 Aug;50(6):611-8. doi: 10.3109/13693786.2012.669502. Epub 2012 Mar 21.

28.

A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.

Brass EP, Cooper LT, Morgan RE, Hiatt WR.

J Vasc Surg. 2012 Feb;55(2):381-389.e1. doi: 10.1016/j.jvs.2011.09.004. Epub 2011 Nov 25.

29.

Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment.

Brass EP, Lofstedt R, Renn O.

Clin Pharmacol Ther. 2011 Dec;90(6):791-803. doi: 10.1038/clpt.2011.231. Epub 2011 Nov 2.

PMID:
22048228
30.

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP.

J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.

31.

Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia.

Spellberg B, Lewis RJ, Boucher HW, Brass EP.

Clin Investig (Lond). 2011 Jan 1;1(1):19-32.

32.

Improving the FDA's advisory committee process.

Brass EP, Hiatt WR.

J Clin Pharmacol. 2012 Aug;52(8):1277-83. doi: 10.1177/0091270011412962. Epub 2011 Sep 10. No abstract available.

PMID:
21908879
33.

The influence of need for cognition and principal display panel factors on over-the-counter drug facts label comprehension.

Catlin JR, Pechmann C, Brass EP.

Health Commun. 2012;27(3):264-72. doi: 10.1080/10410236.2011.578335. Epub 2011 Sep 7.

PMID:
21899401
34.

Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.

Lewis RJ, Connor JT, Teerlink JR, Murphy JR, Cooper LT, Hiatt WR, Brass EP.

Trials. 2011 May 25;12:134. doi: 10.1186/1745-6215-12-134.

35.

Considerations in the development of drugs to treat sarcopenia.

Brass EP, Sietsema KE.

J Am Geriatr Soc. 2011 Mar;59(3):530-5. doi: 10.1111/j.1532-5415.2010.03285.x. Epub 2011 Mar 1. Review.

PMID:
21361879
36.

Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.

Hiatt WR, Creager MA, Amato A, Brass EP.

J Cardiopulm Rehabil Prev. 2011 Mar-Apr;31(2):125-32. doi: 10.1097/HCR.0b013e3181f1fd65.

PMID:
20861750
37.

Should the guidelines for management of central venous catheters in patients with candidemia be changed now?

Brass EP, Edwards JE.

Clin Infect Dis. 2010 Aug 1;51(3):304-6. doi: 10.1086/653936. No abstract available.

PMID:
20578828
38.

Potential biomarkers of muscle injury after eccentric exercise.

Sietsema KE, Meng F, Yates NA, Hendrickson RC, Liaw A, Song Q, Brass EP, Ulrich RG.

Biomarkers. 2010 May;15(3):249-58. doi: 10.3109/13547500903502802.

PMID:
20028270
39.

The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making.

Brass EP.

Clin Pharmacol Ther. 2010 Mar;87(3):351-5. doi: 10.1038/clpt.2009.218. Epub 2009 Dec 9. Review. No abstract available.

PMID:
20010554
40.

Basic biomedical sciences and the future of medical education: implications for internal medicine.

Brass EP.

J Gen Intern Med. 2009 Nov;24(11):1251-4. doi: 10.1007/s11606-009-0998-5. Epub 2009 Oct 31. Review.

41.

Sixty years of Pharmacological Reviews: has the role of review articles in biomedical sciences changed and, if so, how does this affect Pharmacological Reviews?

Brass EP, Feldman RD.

Pharmacol Rev. 2009 Jun;61(2):115-8. doi: 10.1124/pr.109.001594. No abstract available.

PMID:
19549925
42.

Temporal pattern of skeletal muscle gene expression following endurance exercise in Alaskan sled dogs.

Brass EP, Peters MA, Hinchcliff KW, He YD, Ulrich RG.

J Appl Physiol (1985). 2009 Aug;107(2):605-12. doi: 10.1152/japplphysiol.91347.2008. Epub 2009 Jun 4.

43.

Analysis of multiple end points in consumer research in support of switching drugs from prescription to over-the-counter status: the concept of end-point hierarchies.

Brass EP, Shay LE, Leonard-Segal A.

Clin Pharmacol Ther. 2009 Apr;85(4):369-74. doi: 10.1038/clpt.2008.254. Epub 2009 Jan 14. Review.

PMID:
19145230
44.

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert DN; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S249-65. Review. No abstract available.

45.

Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study.

Brass EP, Vassil T, Replogle A, Hwang P, Rusche S, Shiffman S, Levine JG.

Am J Cardiol. 2008 May 15;101(10):1448-55. doi: 10.1016/j.amjcard.2008.01.020. Epub 2008 Mar 17.

PMID:
18471457
46.
47.

American and German students' knowledge, perceptions, and behaviors with respect to over-the-counter pain relievers.

Hanoch Y, Katsikopoulos KV, Gummerum M, Brass EP.

Health Psychol. 2007 Nov;26(6):802-6.

PMID:
18020854
48.

Optimal assessment of baseline treadmill walking performance in claudication clinical trials.

Brass EP, Jiao J, Hiatt W.

Vasc Med. 2007 May;12(2):97-103. Review.

PMID:
17615797
49.

Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise.

Chung J, Brass EP, Ulrich RG, Hiatt WR.

Clin Pharmacol Ther. 2008 Feb;83(2):243-50. Epub 2007 Jun 6.

PMID:
17554242
50.

Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.

Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, Hiatt WR; Circulase investigators.

J Vasc Surg. 2007 May;45(5):953-60; discussion 960-1. Epub 2007 Mar 9.

Supplemental Content

Loading ...
Support Center